Showing results (141-150 of 230) with videos related to
Sort By:
Pageof 23
BMJ Open|February 7, 2025
SHoes for Adolescent PatEllofemoral pain: study protocol for the SHAPE Australian community-based, randomised clinical trialKade L Paterson, Sam Shearer, Kim L Bennell, et al.Child Abuse & Neglect|November 3, 2021
Predictors of family violence in North Carolina following initial COVID-19 stay-at-home ordersLaura Machlin, Meredith A Gruhn, Adam Bryant Miller, et al.Journal of Anatomy|August 30, 2021
Architectural anatomy of the quadriceps and the relationship with muscle strength: An observational study utilising real-time ultrasound in healthy adultsDoa El-Ansary, Charlotte J Marshall, Joshua Farragher, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B TrialRakesh Popat, Bradley Augustson, Paul Cannell, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|October 31, 2019
Computed Tomography Angiogram Derived From Computed Tomography Perfusion Done with Low Iodine Volume Protocol Preserves Diagnostic Yield for Middle Cerebral Artery-M2 OcclusionsKaustubh Limaye, Adam Bryant, Girish Bathla, et al.Clinical Lymphoma, Myeloma & Leukemia|January 14, 2014
Aberrant expression of CD13 identifies a subgroup of standard-risk adult acute lymphoblastic leukemia with inferior survivalBakul I Dalal, Areej Al Mugairi, Steven Pi, et al.Leukemia & Lymphoma|June 11, 2014
A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemiaAdam Bryant, Dawn Sheppard, Mitchell Sabloff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.British Journal of Haematology|February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyHang Quach, Liam Fernyhough, Ross Henderson, et al.Child Psychiatry and Human Development|November 14, 2024
Risk and Protective Effects of Need for Approval on Self-Injury in Adolescent GirlsRebekah B Clapham, Zihua Ye, Leah H Somerville, et al.Pageof 23